Healthcare Equipment and Supplies
Company Overview of Microdermics Inc.
Microdermics Inc., a medical device company, focuses on commercializing a hollow microneedle delivery platform for the biopharmaceutical market. It focuses on designing, building, testing, and manufacturing hollow metal microneedles for various therapeutics and traditional intramuscular vaccinations. Microdermics Inc. has a strategic cooperation agreement with Vetter. The company was founded in 2014 and is headquartered in Vancouver, Canada.
027 - 2366 Main Mall
Vancouver, BC V6T 1Z4
Founded in 2014
Key Executives for Microdermics Inc.
Co-Founder and Chief Technology Officer
Co-Founder and Chief Scientific Officer
Co-Founder and Vice President of Engineering & Innovation
Co-Founder, Chief Operating Officer and Vice President of Research & Development
Compensation as of Fiscal Year 2017.
Microdermics Inc. Key Developments
Vetter and Microdermics Enter into a Strategic Cooperation Agreement to Develop Innovative Microneedle Drug Delivery Systems
May 31 17
Vetter and Microdermics Inc. announced that they have entered into a strategic cooperation agreement. The market in novel alternatives to needle injections is forecasted to grow rapidly, reaching in excess of 480 million units by 2030 (Roots Analysis report). Microneedles are a novel technology that can offer promising advantages as an alternative to classical needle injections and other routes of administration, mainly in reducing the injectable dose needed to trigger an immune response and accelerating drug absorption by the body. The roadblocks to commercialization are mainly due to limited investment in scalable aseptic manufacture at the later phases of development. To overcome this hurdle the two companies have joined forces to lever the expertise of both firms and enable late stage process development and device manufacture on a commercial scale. Microdermics microneedle technology is commercially scalable and capable of pain-free injections into the pharmacokinetically beneficial intradermal space, providing improved comfort and treatment to patients. Microdermics has successfully demonstrated the initial safety of its microneedle system, and is planning Phase 1 human clinical trials for vaccine and therapeutic delivery, to be initiated in 2017. The company’s Phase 1 clinical trials to validate the effectiveness and reliability of intradermal delivery are expected to initiate in 2017. Microdermics will focus product development and clinical activities on new delivery methods for existing commercial products, providing innovative methods for partners to differentiate via a novel intradermal delivery system, as well as pursue product life cycle extensions.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 16, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries